482 related articles for article (PubMed ID: 20656072)
21. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
[TBL] [Abstract][Full Text] [Related]
22. Differences in flexibility of active sites of cytochromes P450 probed by resonance Raman and UV-Vis absorption spectroscopy.
Anzenbacher P; Hudecek J
J Inorg Biochem; 2001 Dec; 87(4):209-13. PubMed ID: 11744058
[TBL] [Abstract][Full Text] [Related]
23. An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point.
Youdim KA; Lyons R; Payne L; Jones BC; Saunders K
J Pharm Biomed Anal; 2008 Sep; 48(1):92-9. PubMed ID: 18584988
[TBL] [Abstract][Full Text] [Related]
24. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
25. Binding of quinidine radically increases the stability and decreases the flexibility of the cytochrome P450 2D6 active site.
Berka K; Anzenbacherová E; Hendrychová T; Lange R; Mašek V; Anzenbacher P; Otyepka M
J Inorg Biochem; 2012 May; 110():46-50. PubMed ID: 22459173
[TBL] [Abstract][Full Text] [Related]
26. Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5.
Stiborová M; Poljaková J; Martínková E; Ulrichová J; Simánek V; Dvořák Z; Frei E
Toxicology; 2012 Dec; 302(2-3):233-41. PubMed ID: 22917556
[TBL] [Abstract][Full Text] [Related]
27. Importance of hydrophobic parameters in identifying appropriate pose of CYP substrates in cytochromes.
Ramesh M; Bharatam PV
Eur J Med Chem; 2014 Jan; 71():15-23. PubMed ID: 24269512
[TBL] [Abstract][Full Text] [Related]
28. Spectroscopic observations of β-eudesmol binding to human cytochrome P450 isoforms 3A4 and 1A2, but not to isoforms 2C9, 2C19, and 2D6.
Krenc D; Na-Bangchang K
Xenobiotica; 2022 Feb; 52(2):199-208. PubMed ID: 35139770
[TBL] [Abstract][Full Text] [Related]
29. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.
He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P
Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485
[TBL] [Abstract][Full Text] [Related]
31. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes.
Olesen OV; Linnet K
Drug Metab Dispos; 1997 Jun; 25(6):740-4. PubMed ID: 9193876
[TBL] [Abstract][Full Text] [Related]
32. Dehydrogenation of indoline by cytochrome P450 enzymes: a novel "aromatase" process.
Sun H; Ehlhardt WJ; Kulanthaivel P; Lanza DL; Reilly CA; Yost GS
J Pharmacol Exp Ther; 2007 Aug; 322(2):843-51. PubMed ID: 17502430
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9.
Yale SH; Glurich I
J Altern Complement Med; 2005 Jun; 11(3):433-9. PubMed ID: 15992226
[TBL] [Abstract][Full Text] [Related]
34. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica.
Pan Y; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Pook PC; Er HM; Ong CE
J Ethnopharmacol; 2010 Jul; 130(2):275-83. PubMed ID: 20457244
[TBL] [Abstract][Full Text] [Related]
35. Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts.
Donato MT; Lahoz A; Jiménez N; Pérez G; Serralta A; Mir J; Castell JV; Gómez-Lechón MJ
Drug Metab Dispos; 2006 Sep; 34(9):1556-62. PubMed ID: 16763015
[TBL] [Abstract][Full Text] [Related]
36. Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1.
Jerabek P; Martinek V; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():25-32. PubMed ID: 23353840
[TBL] [Abstract][Full Text] [Related]
37. Substrates of human cytochromes P450 from families CYP1 and CYP2: analysis of enzyme selectivity and metabolism.
Lewis DF; Lake BG; Dickins M
Drug Metabol Drug Interact; 2004; 20(3):111-42. PubMed ID: 15508429
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms.
Lee AJ; Cai MX; Thomas PE; Conney AH; Zhu BT
Endocrinology; 2003 Aug; 144(8):3382-98. PubMed ID: 12865317
[TBL] [Abstract][Full Text] [Related]
39. Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes.
Emoto C; Iwasaki K
Xenobiotica; 2007 Sep; 37(9):986-99. PubMed ID: 17896325
[TBL] [Abstract][Full Text] [Related]
40. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.
Zhang WV; D'Esposito F; Edwards RJ; Ramzan I; Murray M
Drug Metab Dispos; 2008 Dec; 36(12):2547-55. PubMed ID: 18809730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]